Progyny Inc is a benefits management company that specializes in providing fertility and family-building benefits to employers and their employees. The company aims to improve the employee experience through comprehensive fertility solutions, including in vitro fertilization (IVF), egg freezing, and adoption services. Progyny partners with a network of fertility specialists to offer personalized care and support, helping individuals and couples navigate their family-building journeys. By focusing on innovative health services and a tailored approach, Progyny enhances the overall health and well-being of families while also addressing the financial implications of fertility treatments for employers. Read More
Progyny (PGNY) Q3 2025 earnings beat estimates with $313.3M in revenue and $0.45 EPS. The company raised its full-year guidance, driving a positive market reaction.
Fertility benefits company Progyny (NASDAQ:PGNY) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 9.3% year on year to $313.3 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $300.2 million was less impressive, coming in 0.7% below expectations. Its non-GAAP profit of $0.45 per share was 15.4% above analysts’ consensus estimates.
Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing BaseRecord $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025Board Authorizes Up to $200 Million in Share Repurchase Program
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, 2025 after the close of the market on Thursday, November 6, 2025.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Trump may potentially announce new measures to expand access to in-vitro fertilization, including guidance for employers to offer supplemental fertility insurance and steep discounts on key IVF drugs.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before the close of 2025. This aggressive stance comes on the heels of a September rate reduction and is primarily driven
Over the past six months, Progyny’s shares (currently trading at $20.90) have posted a disappointing 9.1% loss, well below the S&P 500’s 18.4% gain. This might have investors contemplating their next move.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.6% gain.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Progyny (NASDAQ:PGNY) and its peers.
The U.S. financial markets are currently at a critical juncture, with the stability of the 10-year Treasury yield hovering steadfastly around the 4% mark. This apparent calm in long-term borrowing costs is proving to be a crucial linchpin for the effectiveness of the Federal Reserve's (Fed) anticipated rate cuts,
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
U.S. Treasury yields have recently experienced a significant decline, with the benchmark 10-year Treasury note falling to its lowest levels since April 2025. This sharp dip in yields reflects a dramatic shift in market sentiment, driven by a weaker-than-expected August jobs report that has intensified investor expectations for aggressive
Shares of fertility benefits company Progyny (NASDAQ:PGNY)
fell 5.1% in the afternoon session after a broader market downturn triggered by a surprisingly weak U.S. labor market report. The decline was not driven by company-specific news, as the fertility benefits provider had recently announced a global expansion. Instead, the move was part of a market-wide negative reaction to new economic data. The report showed that nonfarm payrolls increased by only 22,000 in August, and the jobless rate rose to 4.3%. This sharp cooling in the labor market sparked fears of a more significant slowdown, leading to a flight to safer assets like Treasuries and causing stocks to fall. The negative sentiment was compounded by historical trends, as September is, on average, a seasonally weak month for the stock market.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
